Company Overview and News
LONDON, Sept. 21, 2017 /PRNewswire/ -- Summary GlobalData's new report, "South Africa Contrast Media Injectors Market Outlook to 2022", provides key market data on the South Africa Contrast Media Injectors market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segments - Angiographic Injectors, Computed Tomography (CT) Injectors and Magnetic Resonance Imaging (MRI) Injectors.
PRINCETON, N.J., March 31, 2017 /PRNewswire/ -- Guerbet LLC., subsidiary of Guerbet Group (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, takes note of the recent recommendations issued March 10, 2017 by the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), on Gadolinium-based Contrast Agents - procedure under Article 31 of Directive 2001/83/EC.
Summary GlobalData's new report, "BRIC Contrast Media Injectors Market Outlook to 2022", provides key market data on the BRIC Contrast Media Injectors market. The report provides value, in millions of US dollars, volume (in units) and average prices (USD) within market segements - Angiographic Injectors, Computed Tomography (CT) Injectors and Magnetic Resonance Imaging (MRI) Injectors.
Investors are always looking for stocks that are poised to beat at earnings season and Global Blood Therapeutics, Inc. (GBT - Free Report) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report. That is because Global Blood is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Research and Markets has announced the addition of the "Contrast Media Injectors Market: Global Industry Assessment and Forecast, 2015-2025" report to their offering.
PRINCETON, N.J., June 23, 2016 /PRNewswire/ -- Guerbet announced today that it has been named a winner of Premier Inc.'s Supplier Horizon Award.
2018-03-26 - Asif
Overview Global Blood Therapeutics is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company's lead product candidate is voxelotor (previously known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believe inhibits hemoglobin polymerization in sickle cell disease, or SCD. Global Blood Therapeutics is currently evaluating voxelotor in SCD in a Phase 3 clinical trial in adult and adolescent patients with SCD. In addition, Global Blood Therapeutics is evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase 2a clinical trial of adolescent and pediatric patients with SCD, and in July 2017 the company announced that Global Blood Therapeutics has expanded this open-label trial to include a new single-dose cohort in children aged 6-11. In December 2015, the Food and Dr...
7h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
8h - Asif
BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...